Tafamidis cuts deaths, admissions in TTR cardiac amyloidosis
from MedPage Today
Treatment with the investigational drug tafamidis was associated with a reduction in all-cause mortality and cardiovascular hospitalizations in patients with transthyretin (TTR) amyloid cardiomyopathy, and improved functional capacity and quality of life, the phase III ATTR-ACT trial found.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063